WHC is still in active development. Read this to understand our approach.
depiction of BUGYDGFZZOZRHP-UHFFFAOYSA-N.svg
tripsit

memantine

Verificar en tripsit

psychonaut

Memantine

Verificar en psychonaut

isomerdesign

Memantine

Verificar en isomerdesign

pubchem

Memantine

Verificar en pubchem

drugmap

Memantine

Verificar en drugmap

wiki

Memantine

Verificar en wiki

Data

InChI: InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3

Sinónimos: BDBM50062599,DS-3152,3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine,3,5-Dimethyl-1-adamantanamine,Prestwick1_000978,Spectrum_000607,Prestwick3_000978,BPBio1_001117,MEMANTINE [VANDF],Memantine [INN],CBMicro_020348,Prestwick0_000978,Memantine [INN:BAN],BB 0216388,1-amino-3,5-dimethyl adamantane, Namenda XR,A814131,nemdatine,BCP29702,Spectrum5_001355,FT-0649142,KBio2_006223, Memantine (extended release),D 145,SBI-0020417.P004,EN300-103626,DivK1c_000068,DSSTox_RID_80723,Memantinum [INN-Latin],BBL000737,1-Amino-3,5-dimethyladamantane,SPBio_001456,EU-0053634,KBio2_003655,Tricyclo(3.3.1.1(3,7))decan-1-amine, 3,5-dimethyl-,1-amino-3,5-dimethyladamantan,KBio1_000068, Memantine (extended release), Forest,Spectrum4_001022,D-145,Oprea1_480562,memantine,Tox21_110199,UNII-W8O17SJF3T,3,5-dimethyladamantan-1-amine,Exiba (TN),AKOS016340748,W8O17SJF3T,MEMANTINE [HSDB],NSC 757843,3,5-dimethyltricyclo[3.3.1.1^(3,7)]decan-1-amine,CAS-19982-08-2,CCG-204092,GTPL4253,NCGC00015705-07,3,5-Dimethyl-adamantan-1-ylamine,NCGC00015705-03,Memantina,TRICYCLO(3.3.1.1(SUP 3,7))DECAN-1-AMINE, 3,5-DIMETHYL-,SDCCGSBI-0020417.P005,SCHEMBL13213676,DMAA [Antiparkinson Agent],1,3-Dimethyl-5-adamantanamine,AKOS015953276,ALBB-013872,MEMANTINE [MI],AB00053600_14,AB00053600-13,SCHEMBL2688,Spectrum3_000923,KBio3_001926,AB00053600_15,Q412189,AKOS000113995,NCGC00015705-09,NCGC00024782-02,BPBio1_001270,Tox21_110199_1,3,5-DIMETHYLTRICYCLO(3.3.1.1(SUP 3,7))DECAN-1-AMINE,Memantine (INN),NINDS_000068,D145 pound>>D 145 pound>>D-145,CHEBI:64312,Prestwick2_000978,Spectrum2_001408,AB00053600,DSSTox_CID_25174,Memantina [INN-Spanish],Lopac0_000861,3,5-Dimethyl-1-adamantylamine,KBioSS_001087,3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine,1,3-Dimethyl-5-aminoadamantane,3,5-Dimethyl-1-aminoadamantane,STK520682,3,5-dimethyladamantanylamine,SPBio_002926,NCGC00015705-04,Retyliumtosylate,Biomol-NT_000209,3,5-Dimethyl-1-aminoadamantane HCl,DTXSID5045174,D94592,DRG-0267,Memantinum,NCGC00015705-16,DRG 0267,1-amino-3,5-dimethyl-adamantane,DSSTox_GSID_45174,DB01043,NCGC00015705-05,HSDB 7327,Tricyclo[3.3.1.13,7]decan-1-amine, 3,5-dimethyl-,MEMANTINE [WHO-DD],Memantine ER,BSPBio_001015,NCGC00024782-03,Memantine,HMS500D10,IDI1_000068,KBio2_001087,KBioGR_001543,alzantin,CHEMBL807,D08174,NSC-757843,19982-08-2

Estimated data

Solubilidad: -2.017 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 57.2% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.